AbbVie (ABBV) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.91 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.11%. A quarter ago, it was expected that this drugmaker would post earnings of $2.26 per share when it actually produced earnings of $2.31, delivering a surprise of 2.21%.Over the last four quarters, the company has surpa ...

PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this serious, debilitating condition. Moreover, rising healthcare expenditure and presence of favorable reimbursement policies are also contributing to the market expansion. New drugs in development having novel mechanisms of ...

The drug company has a famously strong dividend record -- and that looks set to continue.It was great while it lasted, but AbbVie's (ABBV 1.77%) most important cash cow -- rheumatoid arthritis treatment Humira -- has been out of patent exclusivity in the U.S. since last year. That's not the only change the drugmaker experienced in the past 18 months. AbbVie also replaced its leader as CEO Richard Gonzalez stepped down; Gonzalez had been at the helm since 2013.The pharmaceutical giant delivered excellent ret ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.) _________________________ ...

Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $0.52 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Second-Quarter Net Revenues of $14.462 Billion, an Increase of 4.3 Percent on a Reported Basis and 5.6 Percent on an Operational Basis  Second-Quarter Global Net Revenues from the Immunology Portfolio Were $6.971 Billion, an Increase of 2.3 Pe ...

Arguably, there’s never a bad time to consider trustworthy dividend stocks. By securing passive income, you can complement any returns you generate through speculation. Also, by having dividend-paying companies in your portfolio, you stand a better chance of ending up in positive territory. These factors may become even more critical at this present juncture.Over the weekend, President Joe Biden announced that he would no longer seek reelection. Instead, he will focus on finishing out his term. This massive ...

The second-quarter 2024 reporting cycle of the Medical sector is about to pick up pace this week. The sector mainly comprises pharma/biotech and medical device companies.The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson reported strong second-quarter results, beating estimates for earnings and sales.Swiss pharma giant Novartis AG also reported better-than-expected second-quarter results. Consequently, Novartis increased its operating income growth gui ...

AbbVie (ABBV) will report second-quarter earnings on Jul 25, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.05 billion and $2.56 per share, respectively.Though the company’s earnings estimates have declined from $11.27 per share to $10.81 for 2024 in the past 60 days, they have increased from $12.08 to $12.13 for 2025 during the same period. Image Source: Zacks Investment ResearchEarnings Surprise HistoryAbbVie’s performance has been impressive, with its earnin ...

The big pharma company's top drug is losing ground, but its dividend keeps rising.Shares of Big Pharma company AbbVie (ABBV 0.33%) inched higher recently in response to positive news from a Wall Street investment bank. BMO Capital analyst Evan Seigerman raised his price target on the stock from $180 to $214 per share on Friday, July 19.Bullishness for AbbVie might seem foolhardy to the casual observer. The company's lead drug, Humira, finally lost patent-protected exclusivity in the U.S. market last year, a ...

Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance.Dividend growth stocks typically outperform most other asset classes over five- to 10-year periods. I've selected 10 companies with strong dividend growth records that could amplify your portfolio returns over the long term.These blue-chip companies have navigated various headwinds while continuing to increase their payouts at a blistering rate. Let's examine why these top dividend growers might be worth bu ...